The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•24 February 2026•

1 min read

Palvella Therapeutics Announces Positive Phase 3 Results for SELVA Clinical Trial

Key Facts

1The Phase 3 SELVA study met its primary endpoint with high statistical significance (p < 0.0001).

2The treatment showed significant improvement in Microcystic Lymphatic Malformations using QTORIN 3.9% Rapamycin Anhydrous Gel.

Palvella Therapeutics has announced successful topline results from its Phase 3 SELVA clinical trial evaluating QTORIN 3.9% Rapamycin Anhydrous Gel. The study successfully met its primary endpoint with high statistical significance, recording a p-value of less than 0.0001. The treatment demonstrated significant clinical improvement in patients suffering from microcystic lymphatic malformations, a rare and debilitating condition. This positive outcome represents a major milestone for the company, significantly increasing the probability of regulatory approval and future commercialization. The successful data is expected to pave the way for a regulatory submission to the FDA in the near future. Market analysts view these results as a bullish signal for the biotech sector, potentially impacting related instruments like the XBI and IBB ETFs.